What Bluepharma does

Bluepharma is a privately held Portuguese pharmaceutical company founded in 2001 and headquartered in Coimbra, Portugal. The company operates in the production, development, and marketing of pharmaceutical drugs and maintains a workforce of 501 to 1,000 employees. It is led by founder, CEO, and chairman Paulo Barradas Rebelo and has expanded its capabilities through inorganic moves, including the March 2020 acquisition of Treat U for an undisclosed amount.

Bluepharma's core technology asset is Optomics®, a proprietary, AI-powered platform deployed across the pharmaceutical value chain to accelerate drug development. Optomics® is designed to integrate into real-world clinical settings while supporting regulatory standards for clinical research. In March 2026, Bluepharma entered a strategic collaboration with iLoF to commercialize Optomics®, with initial milestones including a clinical research contract for Alzheimer's disease studies across the United States, Canada, and the United Kingdom. This positions Bluepharma at the intersection of traditional pharmaceutical manufacturing and AI-enabled drug development services.

The company's revenue model is not publicly disclosed in the available sources. Its primary customer segment is the pharmaceutical industry, including pharmaceutical companies and research institutions seeking to accelerate drug development timelines and advance personalized medicine for conditions such as Alzheimer's disease. Bluepharma serves this vertical through drug manufacturing and development, augmented by its AI platform offering. No pricing details, marketing channels, distribution channels, or named end-customer logos are publicly disclosed, limiting visibility into commercial mechanics and customer concentration.

Name

Bluepharma

Website

https://bluepharma.pt

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Bluepharma is a privately held Portuguese pharmaceutical company that produces, develops, and markets drugs. It serves pharmaceutical companies and research institutions through drug manufacturing and its proprietary AI-powered Optomics® platform for accelerating drug development and personalized medicine.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Pharmaceutical manufacturing
• Generic drugs
• Drug development
• AI drug discovery
• Pharmaceutical R&D

Headquarters

HQ city

Coimbra

HQ country

Portugal

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain

Core offering

Bluepharma is a pharmaceutical company engaged in the production, development, and marketing of pharmaceutical drugs. The company has developed a proprietary AI-powered Optomics® technology deployed across the pharmaceutical value chain to accelerate drug development and advance personalized medicine, with current clinical research applications in Alzheimer's disease studies across the US, Canada, and the UK.

Product overview

Bluepharma is a pharmaceutical company that has formed a strategic partnership with iLoF to deploy AI-powered Optomics® technology across the pharmaceutical value chain. Optomics® is their core AI platform technology aimed at accelerating drug development and advancing personalized medicine.

Differentiator

Problem solved

Functional benefit

Products and services

• Optomics®

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• iLoFcoreStrategic or Co-development Partner · 4 March 2026Strategic collaboration to deploy AI-powered Optomics® technology across the pharmaceutical value chain. The partnership aims to accelerate drug development and advance personalized medicine. Initial milestones include a clinical research contract for Alzheimer's disease studies in the US, Canada, and the UK.

Recent moves4 records

Expansion highlights4 records

Emerging players

• Insitro: Insitro applies machine learning to drug discovery and development, using data-driven approaches to identify novel therapeutics. It overlaps with Bluepharma's AI-driven drug development strategy, though it operates as a US-based biotech rather than a manufacturer.
• BenevolentAI: BenevolentAI combines AI with biomedical knowledge graphs to accelerate drug discovery, with particular focus on CNS and rare diseases. It is comparable to Bluepharma's CNS/Alzheimer's direction through the iLoF partnership.

Broad incumbents

• Novartis: Novartis operates across the full pharmaceutical value chain with significant AI/ML investment in drug development. It is a broad incumbent that could either partner with or outcompete Bluepharma's AI-native approach to CNS and personalized medicine.
• Roche: Roche is a global pharmaceutical incumbent that invests heavily in AI-driven drug discovery and has major CNS/Alzheimer's programs. It represents the large incumbent competition Bluepharma's Optomics® platform must compete against for enterprise pharma partnerships.
• Sandoz: Sandoz is a major generic and specialty pharmaceutical manufacturer with a global manufacturing footprint. It represents the broad-incumbent competitor Bluepharma faces in its core generic/branded drug production business.

Direct peers

• Exscientia: Exscientia is an AI-driven pharmatech company focused on end-to-end drug discovery. Its platform approach to AI-enabled drug development closely parallels Bluepharma's Optomics® ambitions across the pharmaceutical value chain.
• iLoF: iLoF is a strategic AI drug-discovery partner of Bluepharma and a direct peer in AI-powered pharmaceutical research. Both deploy AI to accelerate drug development and personalize medicine, making iLoF the most directly comparable partner-competitor in the Optomics® value chain.
• Recursion Pharmaceuticals: Recursion is an AI-native drug discovery company that combines high-throughput biology with machine learning to accelerate pharmaceutical R&D. It is a direct peer to Bluepharma's Optomics® approach of embedding AI across the pharmaceutical value chain.

Regional players

• Laboratórios Vitória: Vitória is a Portuguese pharmaceutical manufacturer with branded and generic drug offerings. It is a regional peer to Bluepharma in the Iberian/Portuguese market with similar manufacturing-and-marketing business models.
• Bial: Bial is a Portuguese pharmaceutical company focused on R&D and commercialization of innovative medicines. It is a regional peer, comparable in scale and Iberian origin to Bluepharma, with overlapping therapeutic-area ambitions including CNS.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/bluepharmasa
• Facebookfacebook.com/bluepharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bluepharma